Showing results (691-700 of 718) with videos related to

Sort By:
Pageof 72
Pharmacoepidemiology and Drug Safety|November 25, 2024
Determining Line of Therapy from Real-World Data in Non-Small Cell Lung CancerConnor B Grady, Wei-Ting Hwang, Joshua E Reuss, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2016
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)A Drilon, G Li, S Dogan, et al.
The New England Journal of Medicine|May 25, 2022
Demethylation and Up-Regulation of an Oncogene after Hypomethylating TherapyYao-Chung Liu, Junsu Kwon, Emiliano Fabiani, et al.
The Lancet. Oncology|June 12, 2021
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 studyJustin F Gainor, Giuseppe Curigliano, Dong-Wan Kim, et al.
Stem Cell Reports|May 10, 2023
Single-cell transcriptome analysis of xenotransplanted human retinal organoids defines two migratory cell populations of nonretinal originYing V Liu, Clayton P Santiago, Akin Sogunro, et al.
JCO Global Oncology|August 22, 2022
The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent ConsiderationsChristian Caglevic, Christian Rolfo, Ignacio Gil-Bazo, et al.
JTO Clinical and Research Reports|August 19, 2024
Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLCWilliam Tompkins, Connor B Grady, Wei-Ting Hwang, et al.
Lung Cancer (Amsterdam, Netherlands)|April 22, 2025
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysisAdam Barsouk, Omar Elghawy, Alex Watts, et al.
Scientific Reports|July 2, 2025
Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumorsJ Abraham, V Domenyuk, N Perdigones, et al.
JCO Precision Oncology|December 22, 2025
CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) FusionsTejas Patil, Jessica J Lin, Parneet K Cheema, et al.
Pageof 72